Press coverage about Anavex Life Sciences Corp. (NASDAQ:AVXL) has trended positive recently, Accern Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Anavex Life Sciences Corp. earned a daily sentiment score of 0.27 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 45.3044962486071 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

A number of equities research analysts recently weighed in on AVXL shares. Zacks Investment Research upgraded Anavex Life Sciences Corp. from a “hold” rating to a “buy” rating and set a $4.75 price objective for the company in a research note on Monday, August 28th. Maxim Group set a $15.00 price objective on Anavex Life Sciences Corp. and gave the stock a “buy” rating in a research note on Monday, August 7th. Noble Financial restated a “buy” rating and set a $15.00 price objective on shares of Anavex Life Sciences Corp. in a research note on Friday, September 29th. Finally, ValuEngine cut Anavex Life Sciences Corp. from a “hold” rating to a “sell” rating in a research note on Tuesday.

Anavex Life Sciences Corp. (NASDAQ:AVXL) traded up $0.04 during trading on Friday, reaching $3.99. The company’s stock had a trading volume of 209,900 shares, compared to its average volume of 410,927. Anavex Life Sciences Corp. has a 52 week low of $3.31 and a 52 week high of $6.64.

TRADEMARK VIOLATION NOTICE: “Anavex Life Sciences Corp. (AVXL) Receives Daily Media Sentiment Rating of 0.27” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.watchlistnews.com/anavex-life-sciences-corp-avxl-receives-daily-media-sentiment-rating-of-0-27/1724313.html.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Insider Buying and Selling by Quarter for Anavex Life Sciences Corp. (NASDAQ:AVXL)

Receive News & Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.